The U.S. Pfizer document revealed vaccine side effects, documenting 160,000 adverse reactions for months

According to Russia Today Television (RT), documents disclosed by the U.S. Food and Drug Administration (FDA) show that U.S. drugmaker Pfizer has recorded nearly 160,000 adverse reactions in the first few months of its COVID-19 vaccine.

Russian Television Today (RT) reports with picture

According to the first Pfizer documents, as of February 2021, when the Pfizer vaccine was urgently rolled out globally, the drugmaker had compiled more than 42,000 reports detailing nearly 160,000 adverse vaccination events.

These adverse reactions ranged from mild to severe, with a total of 1223 deaths among those with adverse reactions. Most of these reports concerned people in the United States between the ages of 31 and 50.

More than 25,000 neurological symptoms were reported, along with 17,000 musculoskeletal and connective tissue symptoms, and 14,000 gastrointestinal symptoms, the documents show. A range of different autoimmune symptoms were also reported, as well as a number of specific diseases, including 270 cases of "spontaneous abortion", as well as thousands of symptoms of herpes, epilepsy, heart failure and stroke.

These side effects are previously known and are recorded in the CDC's Vaccine Adverse Event Reporting System (VAERS) database, which, as of Last Sunday (12th), has tracked 3,300 deaths after pfizer vaccination, a figure broadly consistent with the company's own published figures.

Crucially, the FDA used Pfizer documents to declare the company's vaccine safe and in August that Americans 16 and older could be safely vaccinated. The vaccine has since been approved for children under 5 years of age and was also approved last week for booster injections in people aged 16 and older.

In the face of the Omiljunn variant, which may be more contagious, Pfizer CEO Albert Bourla said on Wednesday (8th) that a fourth dose of vaccine may be needed to maintain a high level of immunity.

According to the report, a study in South Africa showed that the ability of Pfizer vaccine antibodies to clear the virus when targeting Omiljung was about 40 times lower than when targeting the original strain of the new crown virus. Pfizer said that by March 2022, there may be a vaccine for the Aumecreon variant on the market. (Editor: SDY)